C反應性蛋白質檢驗的全球市場
市場調查報告書
商品編碼
1198990

C反應性蛋白質檢驗的全球市場

C-Reactive Protein Testing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球C反應性蛋白質檢驗的市場規模在2022年估算為54億美金,在2022年~2030年的分析期間預計將以-0.2%的年複合成長率增長,到2030年前達到53億美元。

本報告提供全球C反應性蛋白質檢驗市場調查,提供市場概要,市場促進因素的分析,市場機會,各地區的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他的歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP11362

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global C-Reactive Protein Testing Market to Reach $5.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for C-Reactive Protein Testing estimated at US$5.4 Billion in the year 2022, is projected to reach a revised size of US$5.3 Billion by 2030, growing at a CAGR of -0.2% over the analysis period 2022-2030. Cardiovascular Diseases, one of the segments analyzed in the report, is projected to record a 0% CAGR and reach US$1.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cancer segment is readjusted to a revised -0.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at -0.2% CAGR

The C-Reactive Protein Testing market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$950.5 Million by the year 2030 trailing a CAGR of -0.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.1% and -0.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 0% CAGR.

Select Competitors (Total 43 Featured):

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings (LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • C-Reactive Protein Testing - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • What is C-reactive Protein (CRP)?
    • An Introduction to C-reactive Protein Testing
    • Global Market Prospects & Outlook
    • Immunoturbidimetric Assays: The Major Segment by Assay Type
    • hs-CRP Test Type Leads by Detection Range
    • Cardiovascular Diseases Emerge As the Leading Disease Type for CRP Testing, Cancer Detection to Make Strong Gains
    • Clinics & Hospitals Hold Dominant Share of CRP Testing Market
    • Developed Regions Lead, Developing Economies to Spur Market Growth
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prominence of POC Testing Approaches for C-reactive Protein Testing Enable Faster and Accurate Results
    • Growing Approval for CRP Testing for Identification of Bacterial and Non-Bacterial Diseases to Propel Market Growth
    • CRP Testing for Ascertaining Viral Infections
    • Growing Incidence of HIV Infections and Need for Monitoring of HIV Diseases Drive CRP Testing
    • Rising Importance of CRP Testing for Cardiovascular Diseases
    • Cardiovascular Disease Incidence Rates (per 100,000) by Select Countries
    • Rising Prevalence of Inflammatory Diseases: Opportunity for CRP Testing
    • Threat of Endometriosis in Women: Significant Role of CRP Testing
    • CRP Testing: A Vital Diagnostic Tool for Cancer
    • Advancements in CRP Testing Methods
    • CRP Testing Holds Potential Role in Assessing Effectiveness of Antibiotic Drugs
    • Funding Support for Extensive Research on Applications of C-reactive Protein Testing to Boost Market Growth
    • CRP Testing Brings to Light Issues Related to Data Integrity & Testing Reliability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Lupus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 33: World 16-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 36: World 16-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Home by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Home by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 39: World 16-Year Perspective for Home by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 42: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 43: World C-Reactive Protein Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: World 16-Year Perspective for Immunoturbidimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 48: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: World 16-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: World 16-Year Perspective for Chemiluminescence Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: World 16-Year Perspective for Other Assay Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: USA 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: USA 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: USA 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • JAPAN
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • CHINA
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: China Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: China 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: China Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: China 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: China Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: China 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • EUROPE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • FRANCE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: France Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: France 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: France Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: France 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: France Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: France 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • GERMANY
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: UK 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: UK 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: UK 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Rest of World 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 161: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Rest of World Historic Review for C-Reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Rest of World 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2014, 2023 & 2030
    • TABLE 164: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of World Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Rest of World 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2023 & 2030

IV. COMPETITION